Oncotarget

Clinical Research Papers:

Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients

Dawei Chen, Yan Zhang, Fang Shi, Hui Zhu, Minghuan Li, Kaijun Chen, Li Kong and Jinming Yu _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:52436-52441. https://doi.org/10.18632/oncotarget.9420

Metrics: PDF 1585 views  |   HTML 2068 views  |   ?  


Abstract

Dawei Chen1,2,*, Yan Zhang2,3,*, Fang Shi2,3, Hui Zhu2,3, Minghuan Li2,3, Kaijun Chen4, Li Kong2,3 and Jinming Yu2,3

1 Weifang Medical University, Weifang, China

2 Department of Radiation Oncology, Shandong Cancer Hospital affiliated to Shandong University, Jinan, China

3 Shandong Academy of Medical Sciences, Jinan, China

4 Department of Clinical Laboratory, Mengyin People’s Hospital, Linyi, China

* These authors have contributed equally to this work

Correspondence to:

Li Kong, email:

Jinming Yu, email:

Keywords: bevacizumab, intrapericardial, malignant pericardial effusion, advanced cancer

Received: January 14, 2016 Accepted: May 09, 2016 Published: May 17, 2016

Abstract

We evaluated the safety and efficacy of intrapericardial bevacizumab (BEV) for treating symptomatic malignant pericardiac effusion (MPCE) in seven advanced cancer patients. All patients had previously undergone multiple lines of systemic therapy. Each patient received paracentesis and intrapericardial infusions of 100 or 200 mg of BEV every two weeks. Systemic treatments for primary tumors continued for all patients during BEV treatment. Of the seven patients, three achieved a complete response, two achieved a partial response, and two showed no response with regard to MPCE after BEV infusion. The median overall survival time was 168 days (range, 22-224 days). In six of the seven patients, effusion did not recur before death. Toxicity associated with BEV treatment was mild and manageable in all patients. This study provides preliminary evidence that intrapericardial BEV may be an effective and safe treatment for MPCE in patients with advanced cancers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9420